Cook Medical Receives Vizient Contract for Endoscopy Devices

Cook Medical has received a contract with Vizient for endoscopy devices. This new agreement will allow Cook to continue to offer our endoscopy devices at negotiated pricing terms to healthcare facilities that are members of Vizient. With the agreement from Vizient, which is the largest member-driven healthcare performance improvement company in the country, Cook looks forward to making endoscopy products more accessible for physicians and patients across the United States.

For almost 60 years, Cook Medical has collaborated with physicians to develop innovative devices to improve lives around the world. We brought our pioneering model for minimally invasive devices to the field of gastrointestinal (GI) endoscopy to diagnose and treat diseases throughout the gastrointestinal tract. The FDA has granted multiple Cook Endoscopy products FDA Breakthrough Device Designations, including our technologies for hemostasis and endoscopic ultrasound. Now, with this contract, endoscopy products will be more accessible to more patients.

This new Vizient agreement becomes effective April 1, 2023. The agreement will include Cook’s full line of endoscopy medical devices, including Hemospray® Endoscopic Hemostat. The contract will also include products from the following product categories:

  • Biliary access (long wire & short wire)
  • Biliary / pancreatic therapy
  • Biopsy, cytology & polypectomy
  • Extraction, dilation, drainage stenting
  • Stricture management
  • Tissue management
  • Esophageal, gastric, colonic
  • Enteroscopy
  • Hemostasis
  • Endoscopic ultrasound
  • Endobronchial ultrasound
  • Endohepatology
  • Endosurgery

“We are honored to have been chosen as an Endoscopy contracted supplier with Vizient. With over 40 years of expertise in the gastroenterology specialty, Cook Medical looks forward to continuing to work with Vizient members and the physicians that treat patients with our endoscopy medical devices,” said Rick Simms, Cook Medical National GPO Account Executive.

Contracting with Cook Medical has several benefits for hospital systems and healthcare facilities. Cook is dedicated to responsible product creation and consumption as we care for the planet. To learn more about our earth-conscious values, you can read about our initiatives here.

To learn more about our breakthrough products and other initiatives, visit Cook’s Endoscopy page.

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version